Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Bristol-Myers Dumps Exelixis Drug

By Xconomy .com – Updated Apr 6, 2017 at 12:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NYSE: BMY

Bristol Myers Squibb Company

Market Cap

$152B

Today's Change

(-0.81%) -$0.58

Current Price

$70.71

Price as of September 23, 2022, 4:00 p.m. ET

There is an exit payment for Exelixis.

Bristol-Myers Squibb (NYSE: BMY) is backing out of a collaboration with Exelixis (Nasdaq: EXEL) to develop XL184 for cancer. The two companies "were not able to align on the scope, breadth and pace of the ongoing clinical development of XL184" because of progress in Bristol's internal cancer drug pipeline, according to an Exelixis statement. Bristol will pay South San Francisco-based Exelixis $17 million to terminate the partnership. Bristol had already paid Exelixis $240 million as part of the deal first signed in December 2008, according to Reuters. Exelixis CEO George Scangos told the wire service that his company has the resources to develop XL184 on its own "for some time," and added that it may find another partner.

More from Xconomy.com:

Exelixis is a Motley Fool Rule Breakers recommendation.

Luke Timmerman is the National Biotechnology Editor for Xconomy, and the Editor of Xconomy Seattle. You can e-mail him at [email protected], or call 206-624-2374.

Stocks Mentioned

Bristol Myers Squibb Company

BMY

$70.71 (-0.81%) $0.58

Exelixis, Inc.

EXEL

$16.28 (-1.75%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Bristol-Myers Squibb Co (BMY) Q2 2019 Earnings Call Transcript

Golf Clap for Bristol-Myers Squibb

Bristol-Myers Squibb Earnings Up Next

Bristol-Myers Squibb Meets on Revenues, Misses on EPS

Bristol-Myers Squibb Earnings Are on Deck

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

339%

S&P 500 Returns

109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.